公开(公告)号：US20250161315A1

公开(公告)日：2025-05-22

申请号：US19029035

申请日：2025-01-17

Applicant: Genentech, Inc.

Inventor： Mark X. Sliwkowski ,  Scott Holden ,  Stuart Lutzker ,  Jay Tibbitts ,  Nelson L. Jumbe

IPC: A61K31/5365 ,  A61K9/00 ,  A61K31/337 ,  A61K31/416 ,  A61K31/513 ,  A61K31/517 ,  A61K31/5355 ,  A61K31/5377 ,  A61K31/555 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  A61K47/68 ,  C07K16/32 ,  G01N33/50 ,  G01N33/574

Abstract: Combinations of the antibody-drug conjugate trastuzumab-MCC-DM1 and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting tumor cell growth, and for treating disorders such as cancer mediated by HER2 and KDR (VEGFR receptor 1). Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

公开(公告)号：US20230201210A1

公开(公告)日：2023-06-29

申请号：US18111250

申请日：2023-02-17

Applicant: GENENTECH, INC.

Inventor： Mark X. Sliwkowski ,  Scott Holden ,  Stuart Lutzker ,  Jay Tibbitts ,  Nelson L. Jumbe

IPC: A61K31/5365 ,  A61K31/337 ,  A61K31/416 ,  A61K31/513 ,  A61K31/517 ,  A61K31/5355 ,  A61K31/555 ,  A61K39/395 ,  A61K45/06 ,  G01N33/574 ,  A61K47/68 ,  A61K31/5377 ,  G01N33/50 ,  A61K9/00 ,  C07K16/32

CPC classification number: A61K31/5365 ,  A61K31/337 ,  A61K31/416 ,  A61K31/513 ,  A61K31/517 ,  A61K31/5355 ,  A61K31/555 ,  A61K39/39558 ,  A61K45/06 ,  G01N33/57415 ,  A61K47/6803 ,  A61K47/6855 ,  A61K31/5377 ,  G01N33/5011 ,  A61K9/0019 ,  C07K16/32 ,  G01N33/5044 ,  G01N2500/10 ,  G01N2800/52 ,  A61K2039/507

Abstract: Combinations of the antibody-drug conjugate trastuzumab-MCC-DM1 and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting tumor cell growth, and for treating disorders such as cancer mediated by HER2 and KDR (VEGFR receptor 1). Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

公开(公告)号：US20170136026A1

公开(公告)日：2017-05-18

申请号：US15414137

申请日：2017-01-24

Applicant: GENENTECH, INC.

Inventor： Mark X. Sliwkowski ,  Scott Holden ,  Stuart Lutzker ,  Jay Tibbitts ,  Nelson L. Jumbe

IPC: A61K31/5365 ,  A61K31/517 ,  A61K39/395 ,  C07K16/32 ,  A61K9/00 ,  A61K31/337 ,  G01N33/50

Abstract: Combinations of the antibody-drug conjugate trastuzumab-MCC-DM1 and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting tumor cell growth, and for treating disorders such as cancer mediated by HER2 and KDR (VEGFR receptor 1). Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.